Nautilus Biotechnology Inc Net Assets
Nautilus Biotechnology Inc net assets. Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has net assets worth $131.11 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($163.58 Million) and total liabilities ($32.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Nautilus Biotechnology Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $131.11 Million |
| % of Total Assets | 80.15% |
| Annual Growth Rate | 63.61% |
| 5-Year Change | -56.83% |
| 10-Year Change | N/A |
| Growth Volatility | 152.01 |
Net Assets of Nautilus Biotechnology Inc (2018–2025)
Net assets of Nautilus Biotechnology Inc from 2018 to 2025. This chart illustrates how Nautilus Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. See NAUT equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Nautilus Biotechnology Inc (2018–2025)
The table below shows the annual net assets of Nautilus Biotechnology Inc from 2018 to 2025. For live market cap and overall valuation, see Nautilus Biotechnology Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $156.97 Million | -24.80% |
| 2024-12-31 | $208.73 Million | -21.34% |
| 2023-12-31 | $265.35 Million | -15.74% |
| 2022-12-31 | $314.92 Million | -13.38% |
| 2021-12-31 | $363.58 Million | +1323.30% |
| 2020-12-31 | $-29.72 Million | -264.64% |
| 2019-12-31 | $18.05 Million | +261.04% |
| 2018-12-31 | $5.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nautilus Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53087.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Nautilus Biotechnology Inc Net Assets Breakdown (December 2025)
Nautilus Biotechnology Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.01% |
| Other Comprehensive Income | $243.00K | 0.15% |
| Other Components | $488.74 Million | 311.35% |
| Total Equity | $156.97 Million | 100.00% |
Nautilus Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Nautilus Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Compucase Enterprise Co Ltd
TW:3032
|
$231.64 Million |
|
BTB Real Estate Investment Trust
TO:BTB-UN
|
$231.78 Million |
|
Launchpad Cadenza Acquisition Corp I Class A Ordinary Share
NASDAQ:LPCV
|
$231.84 Million |
|
Ammo Inc
NASDAQ:POWW
|
$231.88 Million |
|
Zhejiang Prulde Electric Appliance Co. Ltd. A
SHE:301353
|
$231.60 Million |
|
Australian Strategic Materials Ltd
AU:ASM
|
$231.37 Million |
|
Doubleview Gold Corp
V:DBG
|
$231.35 Million |
|
Huasi Agricultural Development Co Ltd
SHE:002494
|
$231.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nautilus Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 208,730,000 to 156,973,000, a change of -51,757,000 (-24.8%).
- Net loss of 59,001,000 reduced equity.
- Share repurchases of 156,000 reduced equity.
- Other comprehensive income increased equity by 186,000.
- Other factors increased equity by 7,214,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.00 Million | -37.59% |
| Share Repurchases | $156.00K | -0.1% |
| Other Comprehensive Income | $186.00K | +0.12% |
| Other Changes | $7.21 Million | +4.6% |
| Total Change | $- | -24.80% |
Book Value vs Market Value Analysis
This analysis compares Nautilus Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.38x to 1.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.70 | $2.35 | x |
| 2019-12-31 | $2.98 | $2.35 | x |
| 2020-12-31 | $-0.90 | $2.35 | x |
| 2021-12-31 | $4.30 | $2.35 | x |
| 2022-12-31 | $2.53 | $2.35 | x |
| 2023-12-31 | $2.12 | $2.35 | x |
| 2024-12-31 | $1.66 | $2.35 | x |
| 2025-12-31 | $1.24 | $2.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nautilus Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-37.59%) is below the historical average (1543.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 12532.00% | 0.00% | 0.00x | 29.16x | $626.10 Million |
| 2019 | -53.28% | 0.00% | 0.00x | 1.03x | $-11.42 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.65 Million |
| 2021 | -13.84% | 0.00% | 0.00x | 1.10x | $-86.67 Million |
| 2022 | -18.39% | 0.00% | 0.00x | 1.11x | $-89.42 Million |
| 2023 | -24.00% | 0.00% | 0.00x | 1.15x | $-90.21 Million |
| 2024 | -33.91% | 0.00% | 0.00x | 1.16x | $-91.65 Million |
| 2025 | -37.59% | 0.00% | 0.00x | 1.22x | $-74.70 Million |
Industry Comparison
This section compares Nautilus Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nautilus Biotechnology Inc (NAUT) | $131.11 Million | 12532.00% | 0.25x | $231.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument,… Read more